Thrombotic thrombocytopenic purpura (TTP) is a rare but serious disorder characterized by a blood clotting disorder that leads to the formation of blood clots in microvessels and a decrease in platelet levels. This condition is primarily associated with abnormal activity of the enzyme ADAMTS13, which is responsible for the degradation of von Willebrand factor multimers, which leads to their accumulation and formation of blood clots. The main manifestations of the disease are purpura (skin hemorrhages), anemia, thrombocytopenia and signs of organ damage, which can lead to serious complications, including death, if not treated promptly. TTP can be either primary (hereditary) or secondary, developing as a result of various provoking factors, including infections, pregnancy and some tumors.
History of the disease and interesting historical facts
The history of thrombotic thrombocytopenic purpura dates back to the early 20th century, when the English physician George MH Van der Linden first described the clinical manifestations of the disease in 1924. However, the development of the understanding of the pathogenesis of TTP occurred much later, especially after the discovery of the role of the enzyme ADAMTS13 in 2001. This discovery allowed a better understanding of the molecular mechanisms underlying the disease and gave rise to new approaches to diagnosis and treatment. In the 1950s, TTP was described as an acute condition that could be treated with plasma exchange, which revolutionized the approaches to therapy and monitoring in patients with this diagnosis. The study of TTP has also led to significant progress in the introduction of new drugs, such as recombinant ADAMTS13.
Epidemiology
Thrombotic thrombocytopenic purpura is rare, with an incidence of about 3.7 cases per million people per year. In general, the incidence is slightly higher in women than in men, and the disease usually appears between the ages of 20 and 50 years. Studies show that the secondary form of the disease is more common in patients with comorbid conditions, such as systemic diseases or infections. Some epidemiological studies have noted a higher incidence of TTP in women under 40 years of age, especially during pregnancy. A recent review has shown an increase in the number of cases in certain regions, which may be due to environmental factors or climate change.
Genetic predisposition to this disease
Genetic predisposition to thrombotic thrombocytopenic purpura is associated with mutations in the ADAMTS13 gene, which codes for an enzyme responsible for the degradation of von Willebrand factor multimers. More than 200 mutations in this gene have been identified, and they can lead to decreased or absent enzyme activity. The hereditary form of the disease is often associated with recessive mutations, while acquired forms can arise due to secondary influences. It is important to note that the presence of mutations in the ADAMTS13 gene does not always guarantee the development of the disease, and environmental factors can play a key role in its manifestation.
Risk factors for the development of this disease
The main risk factors that contribute to the development of thrombotic thrombocytopenic purpura include the following:
- Autoimmune diseases (eg, systemic lupus erythematosus).
- Infectious diseases (including HIV and infectious mononucleosis).
- Oncological diseases such as breast cancer.
- Pregnancy and postpartum period.
- Some medications (eg, antitumor drugs).
- Liver diseases.
Please note that the presence of one or more of these factors does not necessarily lead to the development of TTP, but they may contribute to its occurrence if certain predisposing conditions are present.
Diagnosis of this disease
Diagnosis of thrombotic thrombocytopenic purpura involves a comprehensive approach:
1. Main symptoms:
- Skin hemorrhages (purpura).
- Anemia of varying severity.
— Neurological disorders (headaches, confusion).
— Symptoms of cardiovascular diseases.
2. Laboratory tests:
— Complete blood count (detection of thrombocytopenia and anemia).
— Determination of the level of the ADAMTS13 enzyme and its antibodies.
— Determination of the presence of multidimensional forms of the von Willebrand factor.
3. Radiological examinations:
— Ultrasound diagnostics to detect organ damage.
— CT or MRI if there are neurological symptoms.
4. Other types of diagnostics:
— Determination of lactate dehydrogenase (LDH) and bilirubin levels.
— Research for the presence of autoantibodies.
5. Differential diagnosis:
- Hellp syndrome.
- Acute leukemia.
— Moderate or severe thrombocytopenia (eg, in idiopathic thrombocytopenic purpura).
Each of these components plays an important role in the timely and accurate diagnosis of TTP, which is critical for effective treatment.
Treatment
Treatment of thrombotic thrombocytopenic purpura requires an immediate and comprehensive approach:
1. General treatment:
— Plasmapheresis: removal of plasma containing antibodies against ADAMTS13 and its replacement with fresh frozen plasma.
2. Pharmacological treatment:
- Glucocorticosteroids (eg, prednisolone) to reduce the inflammatory response.
- Immunosuppressants (such as cyclosporine) to control the autoimmune reaction.
— Blondozolizumab to inhibit the activity of antibodies against ADAMTS13.
3. Surgical treatment:
— In rare cases, selective splenectomy may be used for severe forms of the disease.
4. Other types of treatment:
— Antibiotic therapy in the presence of infections that provoke TTP.
- Symptomatic treatment (platelet transfusions, if necessary).
These approaches are often combined to achieve the best therapeutic outcome.
List of medications used to treat this disease
Medications used to treat thrombotic thrombocytopenic purpura include:
- Prednisolone
- Cyclosporine
- Recombinant ADAMTS13
- Blancosolizumab
- Antibiotics (if there are infections)
The use of these drugs should be carried out under the supervision of specialists and in accordance with established treatment protocols.
Disease monitoring
Monitoring the condition of patients with thrombotic thrombocytopenic purpura includes several key steps:
1. Control stages:
— Regular blood tests to assess hemoglobin and platelet levels.
— Monitoring the activity of the ADAMTS13 enzyme.
2. Forecast:
— The prognosis depends on how quickly treatment is started. Timely diagnosis and treatment can significantly improve the outcome of the disease.
3. Complications:
— Relapses of the disease are possible, as well as complications from organs such as the kidneys or central nervous system, which requires constant monitoring.
Age-related features of the disease
Thrombotic thrombocytopenic purpura can occur in different age groups, but has its own characteristics in children and the elderly:
— In children, TTP is often secondary and may be associated with infections or other diseases. The symptomatic picture may be less pronounced than in adults.
— In older people, TTP may present with severe complications, including more pronounced neurological symptoms and risky comorbid conditions. At this stage of treatment, a more gentle approach may be required, taking into account the overall condition of the patient.
Questions and Answers
- What is thrombotic thrombocytopenic purpura?
It is a rare disorder associated with the formation of blood clots in small vessels and a decrease in platelet levels, most often caused by a deficiency of the enzyme ADAMTS13. - What are the main symptoms of TTP?
The condition is characterized by cutaneous hemorrhages, anemia, neurological symptoms and thrombocytopenia. - How is TTP diagnosed?
Diagnosis includes blood tests for platelet levels, ADAMTS13 activity, and other laboratory tests. - How is TTP treated?
Treatment includes plasmapheresis, the use of glucocorticosteroids and immunosuppressants, as well as symptomatic therapy. - What is the prognosis for TTP?
The prognosis depends on the speed and adequacy of treatment; timely intervention can significantly improve the outcome.
These questions and answers will help you better understand the nature of the disease and the main aspects of its diagnosis and treatment.
